This trial aims to enhance immune function in CLL patients through early treatment intervention, employing a short 12-week course of the BTK inhibitor acalabrutinib and the BCL-2 inhibitor venetoclax in patients with high-risk features based on the CLL-TIM algorithm [29, 40]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.